Science 37 to be Acquired by eMed, Expanding Access to Patients and Accelerating Enrollment
RESEARCH TRIANGLE PARK, N.C., Jan. 29, 2024 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (Nasdaq:SNCE) (the “Company” or “Science 37”), the clinical research industry’s leading MetasiteTM, today announced that it has entered into a definitive merger agreement to be acquired by eMed, LLC (“eMed”), the leader in on-demand virtual care and treatment for consumers. With the most authoritative in-home testing and treatment solution available across a variety of indications, the largest real-time network of certified remote proctors, and Test-to-TreatTM technology that streamlines the patient enrollment process, eMed brings significant resources to enhance Science 37’s ability to access unique patients, enroll studies faster, and ensure long-term sustainability.